William Blair Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Promising Developments in Cardiff Oncology's Cancer Treatment Boost Buy Rating
Cardiff Oncology Announces Second Patent for Onvansertib Combination
Express News | Cardiff Oncology Announces a Second Patent for the Treatment of Mcrc for Bev-Naïve Patients
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF), UnitedHealth (UNH) and McKesson (MCK)
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Express News | Cardiff Oncology Inc - Additional Clinical Data From Crdf-004 Trial Expected in 1H 2025
Express News | Cardiff Oncology Inc - Primary Endpoint Is Objective Response Rate, Secondary Endpoints Include Pfs, Dor, Safety
Cardiff Oncology Completes Patient Enrollment In Ongoing Phase 2 CRDF-004 Trial Evaluating Onvansertib In Combination With SoC For Treatment Of First-line RAS-mutated MCRC
Express News | Cardiff Oncology Announces Completion of Enrollment in Phase 2 Crdf-004 Trial Evaluating Onvansertib for the Treatment of First-Line Ras-Mutated Metastatic Colorectal Cancer
Piper Sandler Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Lucid Capital Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $14
Cardiff Oncology Initiated With a Buy at Lucid Capital
Cardiff Oncology Surges 18%
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations
H.C. Wainwright Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $17